Investment Analysts’ Weekly Ratings Changes for Cytokinetics (CYTK)

Cytokinetics (NASDAQ: CYTK) recently received a number of ratings updates from brokerages and research firms:

• 1/21/2026 – Cytokinetics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/21/2026 – Cytokinetics had its price target raised by analysts at B. Riley from $90.00 to $108.00. They now have a “buy” rating on the stock.
• 1/21/2026 – Cytokinetics had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $95.00 price target on the stock.
• 1/20/2026 – Cytokinetics had its price target raised by analysts at JPMorgan Chase & Co. from $70.00 to $74.00. They now have an “overweight” rating on the stock.
• 1/9/2026 – Cytokinetics had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $90.00 price target on the stock.
• 1/8/2026 – Cytokinetics was given a new $90.00 price target on by analysts at Morgan Stanley.
• 12/22/2025 – Cytokinetics was given a new $84.00 price target on by analysts at Truist Financial Corporation.
• 12/22/2025 – Cytokinetics had its price target raised by analysts at Morgan Stanley from $65.00 to $71.00. They now have an “overweight” rating on the stock.
• 12/22/2025 – Cytokinetics was given a new $83.00 price target on by analysts at Leerink Partners.
• 12/22/2025 – Cytokinetics had its price target raised by analysts at Royal Bank Of Canada from $87.00 to $95.00. They now have an “outperform” rating on the stock.
• 12/22/2025 – Cytokinetics had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/22/2025 – Cytokinetics had its price target raised by analysts at HC Wainwright from $120.00 to $136.00. They now have a “buy” rating on the stock.
• 12/22/2025 – Cytokinetics had its price target raised by analysts at Barclays PLC from $82.00 to $87.00. They now have an “overweight” rating on the stock.
• 12/22/2025 – Cytokinetics had its price target raised by analysts at Needham & Company LLC from $72.00 to $84.00. They now have a “buy” rating on the stock.
• 12/22/2025 – Cytokinetics had its price target raised by analysts at Citizens Jmp from $78.00 to $88.00. They now have a “market outperform” rating on the stock.
• 12/18/2025 – Cytokinetics was given a new $95.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a “buy” rating on the stock.
• 12/18/2025 – Cytokinetics was upgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “buy” rating. They now have a $95.00 price target on the stock, up previously from $55.00.
• 12/12/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
• 12/1/2025 – Cytokinetics had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $61.00 price target on the stock.

Insider Activity

In related news, EVP Andrew Callos sold 52,486 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $65.95, for a total value of $3,461,451.70. Following the transaction, the executive vice president owned 50,660 shares in the company, valued at approximately $3,341,027. This trade represents a 50.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $62.86, for a total transaction of $314,300.00. Following the sale, the chief executive officer owned 358,108 shares of the company’s stock, valued at approximately $22,510,668.88. This represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 155,169 shares of company stock valued at $10,090,784 in the last ninety days. 3.40% of the stock is owned by company insiders.

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.